title: Direct comparison of in vitro susceptibility of wildtype clinical Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis (CF) to TOBI and BRAMITOB (tobramycin inhalation solutions).
authors.forename: John E
authors.initials: JE
authors.lastname: Moore
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Maeda
authors.forename: Colin E
authors.initials: CE
authors.lastname: Goldsmith
authors.forename: Jacqueline C
authors.initials: JC
authors.lastname: Rendall
authors.forename: J Stuart
authors.initials: JS
authors.lastname: Elborn
mesh_terms: D000280:Administration, Inhalation; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D003550:Cystic Fibrosis / Q000382:microbiology*; D006801:Humans; D008826:Microbial Sensitivity Tests / Q000379:methods; D011552:Pseudomonas Infections / Q000188:drug therapy*; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000302:isolation & purification; D014031:Tobramycin / Q000008:administration & dosage; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D014031:Tobramycin